clipped from: www.mhra.gov.uk The MHRA announced its decision to withdraw co-proxamol in 2005. Since then the vast majority of patients have managed to find an acceptable alternative, after consultation with their health care professional.
The European Medicines Agency (EMEA) has today announced their recommendation to withdraw the marketing authorisations for dextropropoxyphene-containing medicines (including co-proxamol) across the European Union (EU). This recommendation was made after the Committee on Medicinal Products for Human Use (CHMP) concluded that the risks, particularly of potentially fatal overdose, were greater than the medicine’s benefits. The EMEA’s recommendation has been forwarded to the European Commission (EC) for a decision which will be legally binding across the EU. In the UK, the only medicine affected by the EMEA's announcement is co-proxamol.